IMMXImmix Biopharma, Inc.
Earnings
When Immix Biopharma, Inc. reports, what it reported each quarter, and how the stock took the results.
23 quarters. Mar 31, 2021 to Sep 30, 2026. mixed units.
Next results · Q4 2026Projected
10-K due Mar 22 – Apr 2
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 5 filings.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 22 – Apr 2
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$10.65M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- —
- —
- Net income
- -$13.93M
- N/M
- EPS
- -$0.19
- N/M
- Revenue
- —
- —
- Net income
- -$11.56M
- N/M
- EPS
- -$0.18
- N/M
- Revenue
- —
- —
- Net income
- -$10.09M
- N/M
- EPS
- -$0.18
- N/M
- Revenue
- —
- —
- Net income
- -$10.65M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 12, 2026 · after-hours | Nov 12, 2026 | 43 d | 10-Q | — | — | -$0.19 | — | |
| Q2 2026 | Jun 30, 2026 | — | Aug 7, 2026 | 38 d | 10-Q | — | — | -$0.18 | +4.2% | |
| Q1 2026 | Mar 31, 2026 | — | May 7, 2026 | 37 d | 10-Q | — | — | -$0.18 | +2.2% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | — | Mar 25, 2026 | 84 d | 10-K | — | — | — | 2.0% | |
| Q3 2025 | Sep 30, 2025 | — | Nov 7, 2025 | 38 d | 10-Q | — | — | -$0.24 | +2.8% | |
| Q2 2025 | Jun 30, 2025 | — | Aug 8, 2025 | 39 d | 10-Q | — | — | -$0.22 | 3.4% | |
| Q1 2025 | Mar 31, 2025 | — | May 8, 2025 | 38 d | 10-Q | — | — | -$0.15 | 4.5% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | — | Mar 25, 2025 | 84 d | 10-K | — | — | — | +3.4% | |
| Q3 2024 | Sep 30, 2024 | — | Nov 12, 2024 | 43 d | 10-Q | — | — | -$0.24 | 9.3% | |
| Q2 2024 | Jun 30, 2024 | — | Aug 12, 2024 | 43 d | 10-Q | — | — | -$0.15 | — | |
| Q1 2024 | Mar 31, 2024 | — | May 9, 2024 | 39 d | 10-Q | — | — | -$0.22 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | — | Mar 29, 2024 | 89 d | 10-K | — | — | — | 4.2% | |
| Q3 2023 | Sep 30, 2023 | — | Nov 13, 2023 | 44 d | 10-Q | — | — | -$0.23 | 2.8% | |
| Q2 2023 | Jun 30, 2023 | — | Aug 11, 2023 | 42 d | 10-Q | — | — | -$0.24 | — | |
| Q1 2023 | Mar 31, 2023 | — | May 12, 2023 | 42 d | 10-Q | — | — | -$0.18 | 3.3% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | — | Mar 27, 2023 | 86 d | 10-K | — | — | — | 9.6% | |
| Q3 2022 | Sep 30, 2022 | — | Nov 9, 2022 | 40 d | 10-Q | — | — | -$0.11 | +6.1% | |
| Q2 2022 | Jun 30, 2022 | — | Aug 12, 2022 | 43 d | 10-Q | — | — | -$0.11 | — | |
| Q1 2022 | Mar 31, 2022 | — | May 13, 2022 | 43 d | 10-Q | — | — | — | 7.6% | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | — | Mar 28, 2022 | 87 d | 10-K | — | — | — | — | |
| Q3 2021 | Sep 30, 2021 | — | — | — | — | — | — | — | — | |
| Q2 2021 | Jun 30, 2021 | — | — | — | — | — | — | — | — | |
| Q1 2021 | Mar 31, 2021 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2021 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR